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The homophilic potential emerges as an important biological principle to boost the 
potency of immunoglobulins. Since homophilic antibodies in human and mouse sera 
exist prior environmental exposure, they are part of the natural antibody repertoire. 
Nevertheless, hemophilic properties are also identified in induced antibody repertoire. 
The use of homophilicity of antibodies in the adaptive immunity signifies an archetypic 
antibody structure. The unique feature of homophilicity in the antibody repertoire also 
highlights an important mechanism to boost the antibody potency to protect against 
infection and atherosclerosis as well to treat cancer patients.
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nATURAL AnTiBODieS – THe viRGin iMMUne ReSPOnSe
Natural antibodies are immunoglobulins in sera of mammalians that are neither immunologically 
challenged nor responding. For example, natural antibodies are in sera of neonatal or germ-free 
mice. Natural antibodies are of IgM, IgG, and IgA isotypes and play an important role in the immune 
homeostasis and protection against pathogens (1–6). B1 cells in mice produce natural antibod-
ies (7, 8). In human, CD20+CD27+CD43+ memory B cells were recently identified as murine B1 
counterpart (9). Natural antibodies are the important components of the therapeutic intravenous 
immunoglobulin (IVIG) (10–12) that is widely used in the therapy of autoimmune and inflamma-
tory diseases (13–17). These functions of natural antibodies also indicate diverse roles played by 
B cells in the immune homeostasis (18–22).
THe iDiOTYPiC inTeRACTiOnS
Oudin and Jerne are the founders of the idiotype concept (23, 24). They “discovered” that one anti-
body could recognize another antibody as an individual and unique member of the immune system. 
The uniqueness of an antibody lies in the variable region of heavy and light chains and has been 
named idiotype. The idiotype antibody individuality is separated from the antigen-binding site, also 
determined by unique sequence variability. However, both regions are linked by a unique variability 
and have a functional relation. Identifying an antigen-binding site also reveals the linked idiotype 
and vice versa, an idiotope reveals the associated antigen specificity. However, there are important 
exceptions to this linkage rule: the so-called common idiotopes (IdX) are expressed on antibodies 
with different antigen specificities (25). Furthermore, antigen-binding site and idiotype site can be 
identical or overlapping.
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Studies on the functional interactions of anti-idiotype 
binding to antibodies have established a classification in the 
idiotype field. Jerne termed anti-idiotypes that do not inter-
fere with the antigen-binding site as Ab2α and anti-idiotypes 
that block the antigen binding as Ab2β (26). Ab2 was further 
differentiated by adding the term Ab2γ to describe Ab2 that 
only partially inhibits antigen binding (27, 28). The Ab2β has 
another unique functional feature. It mimics the antigen by its 
perfect fit into another antigen-binding site. Ab2β has been 
used as an antigen to induce a specific immune response (28). 
Another shared idiotype has been discovered in HIV-infected 
primates (29). This anti-idiotype antibody has been termed as 
Ab2δ (30).
In mice, “prime” antibodies lack the dominant expression of 
certain shared idiotype, such as the so-called T15 idiotype, that 
develops weeks after birth without environmental challenge (31, 
32). Therefore, the T15 dominance can be considered a part of 
the natural antibody repertoire. The T15 idiotype is also present 
in primates, including man (33). Perhaps a review of the idi-
otypic circuits is helpful for the understanding of the biological 
and immunological properties of the T15 archetypic idiotype. 
A hallmark of the T15 antibody family is their ability to self 
bind for producing homophilic complexes (34–36). The domain 
responsible for antibody self-binding (homophilicity) has been 
described as a region in VH of T15, extending from CDR2 to 
Fr3 (35, 37). Because of their preimmune presence in normal 
sera, homophilic antibodies are segment of the natural antibody 
repertoire (33, 37).
THe BiOLOGY AnD iMMUnOReGULATORY 
FUnCTiOnS OF HOMOPHiLiC AnTiBODieS
The homophilic domain in antibodies was identified, and pep-
tides that can confer the homophilic effect to other antibodies 
were made (38). Further studies showed that the homophilic 
domain can be expressed independently from the specificity of 
the antigen-binding site (39). This suggested that any antibody 
could be made homophilic by attaching the homophilic domain. 
In early experiments, a chemical affinity conjugation method was 
introduced to make the homophilic Ig (40); later, recombinant 
techniques were used to produce a homophilic antibody fusion 
protein.
Human and mouse sera contain antibodies that express the 
homophilic domain (33), confirming that homophilic antibodies 
are part of the so-called natural antibodies (41). Homophilic anti-
bodies with specificity for phosphorylcholine (PC) are superior 
in protecting against Streptococcus pneumoniae infection (42). 
Homophilic anti-PC antibodies are also highly effective to reduce 
atherosclerotic plaque formation (43, 44) and perhaps have other 
housekeeping functions. Antigenicity of the homophilic domain 
was tested in mice, rabbits, and non-human primates by inject-
ing the homophilic domain peptide and treating macaques with 
a homophilic anti-CD20 antibody (45). No antibodies could be 
detected against the homophilic domain. This finding suggests 
that homophilic antibodies could be used as therapeutic drugs to 
treat human diseases without allergic side effects (46).
Indeed, human natural antibodies with specificity for PC 
protect against atherosclerotic plaque formation by binding 
to oxidized LDL and inhibit macrophage activation (43, 47). 
Immunizing atherosclerotic mice with PC antigen reduces 
plaque formation (44). Silverman and colleagues showed that SLE 
patients with low natural antibodies develop more serious disease 
(48). Emerging evidence suggested that natural antibodies could 
control transplant rejection (49).
Another “natural” antibody in normal human sera has been 
described with specificity for HLA (50). This anti-HLA is not 
detectable in sera but is revealed after IgG purification. The 
homophilic T15 peptide from the complementarity-determining 
region/framework masked the HLA recognition of non-purified 
IgG. Since the T15 homophilic peptide dissociate the homophilic 
Ig complex, thereby reducing the polyvalency and binding 
potency, one can conclude that in sera, auto-anti-HLA antibodies 
are bound to corresponding HLA and are not detected. It follows 
that natural auto-anti-HLA antibodies are homophilic. Thus, the 
homophilic property of antibodies plays a role in the functional 
regulation of antibodies either by masking them or by exposing 
them under appropriate conditions.
A homophilic state of the Ig B-cell receptor (BCR) has been 
described in chronic lymphocytic leukemia (51, 52). Peptides 
from the VH Ig BCR bind to the BCR providing the basis for self-
recognition of the BCR. Recently, we used the T15 homophilic 
peptide to inhibit proliferation of murine human B-cell lines (46).
THe UniQUe BiOPHYSiCAL PROPeRTieS 
OF HOMOPHiLiC AnTiBODieS
Working with homophilic-converted Trastuzumab (Herceptin), 
we discovered that the dose–response in inducing apoptosis in a 
Her2/neu-expressing human cell line was not linear but was bell 
shaped (53). The highest concentration tested did not induce the 
highest amount of apoptosis, but a lower concentration produced 
the most apoptosis. Similar non-linear dose effects were observed 
in fluorescence staining of tumor cells. This paradoxical dose 
effect was also observed in xenograft experiment (54).
This non-linear dose affecting the potency of homophilic 
Herceptin could be due to the inherent mechanic of self-binding 
that was observed in 1986 (37, 55). Here, self-binding of the T15 
antibody decreases as the concentration of homophilic antibody 
increases, producing a bell-shaped pattern. This indicates that the 
equilibrium of self-bound antibody and free antibody is controlled 
by the concentration of homophilic antibody. Thus, the lattice of 
build up of homophilic antibodies at the tumor target cell would 
decrease at a higher concentration, thereby reducing apoptosis. 
This paradoxical effect has been observed with homophilic anti-
Her2/neu (Herceptin) (54). In this study, we showed that the 
viscosity of homophilic antibodies increases with temperature 
and decreases at lower temperature, an effect not observed with 
the most other proteins or organic compounds. Furthermore, 
the binding to antigen by a homophilic antibody is also higher at 
physiological temperature than by the non-homophilic parental 
antibody. Lastly, the binding of homophilic Herceptin to tumor 
cells is concentration dependent, whereby a lower concentration 
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targets better than a higher concentration. The unique biophysi-
cal properties of homophilic antibodies represent another aspect 
in the natural antibody repertoire.
HOMOPHiLiCiTY in SHAReD iDiOTYPeS
We believe that we are only at the beginning to discover networks 
of shared idiotypes. By using polyclonal anti-idiotype antibodies, 
Urbain and colleagues have observed shared idiotypes expressed 
on antibodies with different antigen specificity in rabbits and mice 
(26, 56). The monoclonal 1F7 anti-idiotype recognizes antibodies 
against viral antigens and is first described in humans (29, 57, 58). 
The T15 and 1F7 idiotypic networks harbor important biological 
and medical properties: dominant T15 antibodies protect against 
pneumococcal infection (59) and perform a housekeeping 
function to reduce atherosclerotic plaque formation (43); the 
1F7 idiotope is expressed on antibodies against HIV-1 (57, 60) 
and hepatitis C (61, 62) (see also contribution by Muller et al.). 
Furthermore, 1F7-positive human anti-HIV-1 antibodies carry 
the homophilic domain (Veljkovic and Kohler, unpublished). 
These studies on homophilic antibodies show that homophilicity 
is utilized in the innate immunity (natural antibodies) and by the 
adaptive immune response.
HOMOPHiLiCiTY AS A GeneRAL 
COnCePT in SYSTeM BiOLOGY OF 
nATURAL AnTiBODieS
The data on homophilic natural antibodies point to a general 
strategy of enhancing potency not only of antibodies but also 
other biological systems (63). This finding can be viewed as a 
paradigm in System Biology in the T15 and 1F7 idiotypic net-
works. Both systems utilize the antibody homophilicity. Both 
systems also use this property to achieve a high level of antibody 
potency. Antibodies with T15 expression in normal sera are 
close to germline encoding: (i) the T15 dominance develops 
late in ontogeny (31), (ii) the homophilic domain contains H2 
mutations, (iii) analysis of the neonatal repertoire by Coutinho 
(64) shows only evidence for extensive idiotypic network and for 
homophilic binding, and (iv) homophilic antibodies have been 
detected after stimulation (38, 46). Furthermore, in support of 
the adaptive creation of the homophilic domain, the sequence 
of homophilic domains is found different (51, 52). Thus, certain 
homophilic antibodies are not part of the so-called natural anti-
bodies but are induced by antigenic stimulation.
The homophilic antibody enhancement and therapeutic 
potential have been already demonstrated (38, 46). The native 
dominant expression of 1F7 idiotype on anti-HIV-1 antibodies 
may lead to a novel vaccine concept (65). There is one important 
difference between the T15 and the 1F7 system: T15 antibod-
ies are present in preimmune serum without external antigen 
exposure; 1F7 antibodies recognizing anti-HIV and anti-HBC 
antibodies are induced after infection and are not natural anti-
bodies. Nemazee et  al. recently promoted the idea of targeting 
germline antibodies for inducing a maturation sequence, lead-
ing to broadly neutralizing Abs against HIV-1 (66). The use of 
a germline targeting immunogen is different from the concept 
of stimulating B-cells with idiotype expressing receptors. Prior 
to triggering, these B-cells do not produce detectable antibodies 
and do not contribute to the natural antibody repertoire (57). 
Using the 1F7 antibody as vaccine would not require additional 
immunogen(s) to trigger the antibody maturations process, since 
the 1F7 idiotype is expressed by potent broadly neutralizing Abs 
(Parsons, unpublished). HIV-1 infection is expected to stimulate 
the expanded clones of 1F7 expressing B-cells to produce broadly 
neutralizing Abs (57).
SUMMARY
The discussion of the unique feature of homophilicity as a part of 
the natural and induced antibody repertoires (65) highlights an 
important mechanism to boost the antibody potency to protect 
against infection and atherosclerosis (44) as well to treat cancer 
patients (46). The concept of homophilicity is introduced here 
to describe the unique coexistence and synergism of acquired 
immunity with innate immunity. The homophilicity of antibodies 
in the natural and acquired repertoires emerges as an archetypic 
principle in the immune system.
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